ANNAPURNA vs INDOUS: Stock Comparison
ANNAPURNA SWADISHT shows faster revenue growth, while INDO US BIOTECH shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ANNAPURNA leads 3; INDOUS leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ANNAPURNA | INDOUS |
|---|---|---|
| Sector | — | Fast Moving Consumer Goods |
| Industry | — | Other Agricultural Products |
Price
| Metric | ANNAPURNA | INDOUS |
|---|---|---|
| Live Price | ₹136.21 | ₹78.29 |
| Day Change | -1.26% | 0.06% |
| Volume | 12,839 | 2,095 |
| 52-Week High | ₹167 | ₹159 |
| 52-Week Low | ₹132.21 | ₹70 |
| Distance from 52W High | -18.44% | -50.76% |
Valuation
| Metric | ANNAPURNA | INDOUS |
|---|---|---|
| Market Cap | — | ₹160 Cr |
| P/E Ratio | 10.72x | 0x |
| P/B Ratio | 1.05x | 0x |
| EPS | ₹3.65 | ₹1.51 |
| Book Value | ₹151.33 | ₹46.15 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | ANNAPURNA | INDOUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -22% |
| EPS Growth (TTM YoY) | 0% | -47.3% |
| Qtr Sales Growth | -14.57% | 26.75% |
| Qtr Profit Growth | -18.73% | 54.05% |
Profitability & Leverage
| Metric | ANNAPURNA | INDOUS |
|---|---|---|
| ROE | 7.18% | 14.18% |
| ROCE | 6.57% | 12.34% |
| Net Margin | 0% | 11.88% |
| Operating Margin | 11.63% | 14.64% |
| Debt to Equity | 0.64x | 0.4x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | ANNAPURNA | INDOUS |
|---|---|---|
| Promoter Holding | 40.17%▲ 0.29 pp | 68.29% |
| FII Holding | 6.64%▼ 0.66 pp | 0.01%▼ 0.17 pp |
| DII Holding | 0.36%▼ 0.14 pp | — |
| Public Holding | 52.83%▲ 0.5 pp | 31.7%▲ 0.17 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ANNAPURNA SWADISHT and INDO US BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.